Topical Pharmaceutical Composition Synergistic Antimicrobial Action

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current pharmaceutical formulations based on aluminum acetate, such as Burow's solution, have limitations in antimicrobial action and stability, particularly when used at lower concentrations, and are less frequently used in Europe despite their recognized safety and effectiveness in the US.

Innovation Solution

A powder composition comprising calcium acetate, aluminum sulfate, and a third component selected from potassium permanganate or chloramine-T, which can be diluted to achieve enhanced antimicrobial action and astringent effects, allowing for the formation of aqueous dispersions suitable for topical treatment of various skin conditions without the need for filtration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If Burow's solution is used at lower concentrations, then it is safer for skin application, but its antimicrobial action is reduced

Engineering Contradiction:
Improveskin irritationVSAvoidantimicrobial action
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent combines aluminum acetate with chloramine-T or potassium permanganate to create a synergistic antimicrobial formulation. This merging of substances allows the solution to maintain effective antimicrobial action at lower concentrations, thereby reducing skin irritation while preserving therapeutic efficacy.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation by integrating aluminum acetate with oxidizing agents (chloramine-T or potassium permanganate). This composite approach enhances the overall antimicrobial performance, enabling lower concentrations to achieve the same therapeutic effect, thus reducing potential skin irritation while maintaining reliability.

Inventive Principle:
Principle #40Composite materials

2Manufacturing precision

If traditional Burow's solution is prepared with filtration, then purity is improved, but manufacturing complexity increases

Engineering Contradiction:
ImprovepurityVSAvoidfiltration step
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent removes the filtration step from the manufacturing process by formulating a composition that does not require filtration to achieve the desired purity and stability. This extraction of the filtration operation simplifies manufacturing while maintaining product quality.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses a powder composition that can be directly diluted and used without requiring filtration equipment or procedures. This approach eliminates the need for complex manufacturing infrastructure, making the process simpler and more accessible while maintaining effective purity.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition provides a synergistic antimicrobial action at lower concentrations, enabling effective treatment of skin conditions like eczemas, erythemas, and insect bites, with improved stability and usability, including as a cream, lotion, or shampoo, demonstrating enhanced efficacy compared to traditional Burow's solution.

Implementation Method 1

The US Pharmacopeia describes a procedure for the preparation of Burow's solution, which comprises the reaction of aluminum sulfate, calcium carbonate and acetic acid, to form basic aluminum acetate

Methodology Applied
Scientific EffectChemical reaction: Chemical Bonding

Implementation Method 2

A powder composition comprising calcium acetate, aluminum sulfate and a third component selected from potassium permanganate (KMnO4) and chloramine-T

Methodology Applied
Scientific EffectOxidation: Oxidation

Data Source

PatentEP3058945B1Pharmaceutical compositions and formulations for topical application with astringent and antimicrobial effect
Publication Date: 2018.11.14 HIANTIS

AI summary

A powder composition comprising calcium acetate monohydrate, aluminum sulfate tetradecahydrate and a third component selected from potassium permanganate (KMnO4) and chloramine-T (sodium N-chloro-4-toluenesulfonamidate), and a pharmaceutical formulation for topical application comprising the aforementioned components and a pharmaceutically acceptable carrier are described; a pharmaceutical formulation comprising basic aluminum acetate and a component selected from potassium permanganate and chloramine-T is also described; such pharmaceutical formulations are intended for use in the topical treatment of skin conditions such as swelling, hives, eczemas, erythemas, insect bites, bruises, itching, vesicular or bullous exudation, crusted lesions, skin ulcers, atopic dermatitis, herpes zoster, herpes simplex, intertrigo and sunburn.